PYXSHealthcare · BiotechnologyThe 10 Wall Street analysts covering Pyxis Oncology, Inc. hold a median 12-month price target of $8 — +304.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pyxis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (36): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PYXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +304.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $8.00 |
| 10 Sept 2026 | Wedbush | Maintains | Outperform | $6.00 → $8.00 |
| 9 Sept 2026 | Wells Fargo | Maintains | Overweight | $12 → $19 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Aug 2026 | Wells Fargo | Initiates | Overweight | $12 |
| 3 Aug 2026 | Wells Fargo | Initiates | Overweight | — |
| 2 July 2026 | Leerink Partners | Maintains | Outperform | $9.00 → $7.00 |
| 2 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 5 May 2026 | Wedbush | Initiates | Outperform | — |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2026 | Stifel | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Dec 2025 | RBC Capital | Maintains | Outperform | — |
| 24 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 4 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 4 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PYXS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Pyxis Oncology, Inc. returned −41.8% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 9% of US stocks
Cheaper than 9% of US stocks
Cheaper than 72% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 6% of US stocks
Higher than 98% of US stocks
Higher than 8% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pyxis Oncology, Inc. has a market value of $219.8M and an enterprise value of $138.3M.
Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$88.7M, a −803.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$67.9M.
Trailing P/E: −1.4×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pyxis Oncology, Inc. employs 56 people — $197K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pyxis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pyxis Oncology announced that CEO and Chairman Tom Civik will participate in fireside chats at two upcoming investor conferences.
Why it matters — The appearances provide PYXS watchers with opportunities to hear from the company’s CEO and Chairman at upcoming investor conferences.
Pyxis Oncology announced that MICVO monotherapy data in previously treated recurrent/metastatic head and neck squamous cell carcinoma will be featured in a late-breaking oral presentation at the EORTC-NCI-AACR symposium in Barcelona, Nov. 18–20, 2026.
Why it matters — The presentation will provide an update on the clinical program for MICVO in this cancer setting.
Pyxis Oncology's main value driver, the oncology drug candidate MICVO, has shown promising early data but still requires a safe and effective dose. A recent capital raise strengthens the company's near-term financing and should support reaching important clinical milestones with MICVO.
Why it matters — PYXS watchers would care because the strengthened runway helps fund progress on MICVO, the company's key clinical value driver.
Pyxis Oncology closed its previously announced registered public offering on October 1, 2026, generating approximately $110.0 million in upfront gross proceeds before underwriting discounts, commissions, and other expenses. The offering comprised 36,047,919 shares of common stock at $2.90 per share and pre-funded warrants for 1,883,121 shares at $2.899 each, with common warrants for an aggregate of 49,310,352 shares.
Why it matters — The closing of this up to $282.6 million public offering provides Pyxis Oncology with additional capital to support its clinical-stage development of next-generation cancer therapeutics.
Pyxis Oncology priced a registered public offering of 36,047,919 shares of common stock, or pre-funded warrants in lieu of stock to certain investors, along with accompanying common warrants, expecting gross proceeds of approximately $110 million, with up to $172.6 million more if all warrants are exercised.
Why it matters — PYXS watchers would care because the offering provides the clinical-stage company with additional capital to fund its next-generation cancer therapeutics programs.
The 10 Wall Street analysts covering Pyxis Oncology, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Pyxis Oncology, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pyxis Oncology, Inc. 78 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Pyxis Oncology, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +304.0% from the last close, and Ticker Nerd's factor model ranks Pyxis Oncology, Inc. 78 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pyxis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $19 over the next 12 months.
Pyxis Oncology, Inc. returned -41.8% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Pyxis Oncology to Participate in Upcoming Investor Conferences". Pyxis Oncology announced that CEO and Chairman Tom Civik will participate in fireside chats at two upcoming investor conferences.
Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.
CEO Mr. Thomas Civik · 56 employees · United States · https://www.pyxisoncology.com
